Cell division is controlled by a series of positive and negative regulators which act at sequential points throughout the cell cycle. Disturbance of these checks could contribute to cancer by allowing excessive cell proliferation. The point in G1 at which cells irrevocably commit to DMA synthesis is controlled by protein complexes consisting of cyclin-dependent kinases (CDK4 or CDK6) and cyclins (D1, D2 or D3). These complexes are inhibited by low molecular weight proteins, such as p16INK4 (refs 1,2), p15INK4B (ref. 3) and p18 (ref. 4). Deletion or mutation of these CDK-inhibitors could lead to unchecked cell growth, suggesting that members of the p16INK4family may be tumour suppressor genes. The recent detection of p16INK4 (MTS1) mutations in familial melanoma kindreds5,6, many human tumour cell lines7,8, and primary tumours9,10 is consistent with this idea. Previously, we described eight germline p16INK4 substitutions in 18 familial melanoma kindreds5. Genetic analyses suggested that five mutations predisposed carriers to melanoma, whereas two missense mutations had no phenotypic effect. We now describe biochemical analyses of the missense germline mutations and a single somatic mutation detected in these families. Only the melanoma-predisposing mutants were impaired in their ability to inhibit the catalytic activity of the cyclin D1/CDK4 and cyclin D1/CDK6 complexes in vitro. Our data provide a biochemical rationale for the hypothesis that carriers of certain p16INK4 mutations are at increased risk of developing melanoma.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $18.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Serrano, M., Hannon, G.J. & Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366, 704–707 (1993).
Serrano, M., G—mez-Lahoz, E., DePinho, R., Beach, D. & Bar-Sagi, D. Inhibition of Ras-induced proliferation and cellular transformation by p16INK4. Science 267, 249–252 (1995).
Hannon, G.J. & Beach, D. p15INK4B is a potential effector of TGF-_-induced cell cycle arrest. Nature 371, 257–261 (1994).
Guan, K-L. et al. Growth suppression of p18, a P16INK4/MTS1 and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Devel. 8, 2939–2952 (1994).
Hussussian, C.J. et al. Germline p16 mutations in familialmelanoma. Nature Genet. 8, 15–21 (1994).
Kamb, A. et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet. 8, 22–26 (1994).
Kamb, A. et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436–440 (1994).
Nobori, T., Miura, K., Wu, D.J., Lois, A., Takabayashi, K. & Carson, D.A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368, 753–756 (1994).
Caldas, C. et al. Frequent somatic mutations and homozygous deletions of the p16(MTS1) gene in pancreatic adenocarcinoma. Nature Genet. 8, 27–32 (1994).
Mori, T., Miura, K., Aoki, T., Nishihara, T., Mori, S. & Nakamura, M. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res. 54, 3396–3397 (1994).
Goldstein, A.M., Dracopoli, N.C., Engelstein, M., Fraser, M.C., Clark, W.H. Jr. & Tucker, M.A. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am. J. hum. Genet. 54, 489–496 (1994).
MacGeoch, C. et al. Genetic heterogeneity in familial malignant melanoma. Hum. molec. Genet. 3, 2195–2200 (1994).
Bale, S.J. et al. Mapping of the gene for hereditary cutaneous malignant melanoma. New Eng. J. Med. 320, 1367–1372 (1989).
Goldstein, A.M. et al. Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1 p and evidence for genetic heterogeneity. Am. J. hum. Genet. 52, 537–550 (1993).
Cannon-Albright, L.A. et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13–p22. Science 258, 1148–1152 (1992).
Nancarrow, D.J. et al. Confirmation of chromosome 9p linkage in familial melanoma. Am. J. hum. Genet. 53, 936–942 (1993).
Cormack, B. in Current Protocols in Molecular Biology, (eds Ausubel, P.M.) (John Wiley & Sons, New York, 1991).
About this article
The identification of patient‐specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild‐type melanomas
Gene Reports (2019)
CDKN2A founder mutation in pancreatic ductal adenocarcinoma patients without cutaneous features of Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome
Hereditary Cancer in Clinical Practice (2018)
Molecular Genetics & Genomic Medicine (2018)
Journal of Medical Genetics (2017)